KYLE BASS VS POZEN INC. (POZN): PETITION FOR INTER PARTES REVIEW
ValueWalk, 21 May 2015
The Coalition for Affordable Drugs VII LLC (“CFAD” or “Petitioner”) respectfully requests inter partes review of claims 1-23 of U.S. Patent No. 6,926,907 (“the ’907 Patent”) (Ex. 1001) in accordance with 35 U.S.C. §§ 311-319 and 37 C.F.R. § 42.100 et seq. The ’907 Patent is assigned to Pozen Inc. II. Mandatory Notices Per 37 C.F.R. § 42.8
Pursuant to 37 C.F.R. § 42.8(b)(1), CFAD certifies that Coalition For Affordable Drugs VII LLC; Hayman Credes Master Fund, L.P. (“Credes”); Hayman Orange Fund SPC – Portfolio A (“HOF”); Hayman Capital Master Fund, L.P. (“HCMF”); Hayman Capital Management, L.P. (“HCM”); Hayman Offshore Management, Inc. (“HOM”); Hayman Investments, L.L.C. (“HI”); nXn Partners, LLC (“nXnP”); IP Navigation Group, LLC (“IPNav”); J Kyle Bass; and Erich Spangenberg (collectively, “RPI”) are the real parties-in-interest. The RPI certify the following: CFAD is a wholly owned subsidiary of Credes.
